NCT02035657 2018-06-13A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell CarcinomaImmune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Phase 1 Completed10 enrolled